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Abstract  
Chronic inflammation is a common factor in the development of many gastrointestinal 
malignancies. Examples include inflammatory bowel disease predisposing to colorectal 
cancer, Barrett’s esophagus as a precursor of esophageal adenocarcinoma and Helicobacter 
pylori-induced gastric cancer. 
The classical activation pathway of NF-κB signaling has been identified as regulating several 
sporadic and inflammation-associated gastrointestinal tract malignancies. Emerging evidence 
suggests that the alternative NF-κB signaling pathway also exerts a distinct influence on these 
processes. This review brings together current knowledge of the role of the alternative NF-κB 
signaling pathway in the gastrointestinal tract, with a particular emphasis on inflammation-
associated cancer development. 
 
Introduction  
Members of the Nuclear Factor κ-light-chain-enhancer of activated B cells (NF-κB) family were 
initially described as transcription factors in B lymphocytes in 1986[1]. Since then, they have 
been shown to be widely expressed and are conserved across both vertebrates and 
invertebrates[2, 3]. 
The conventional model of NF-κB signaling proposes two main arms of the pathway. These 
share similar features, but are triggered independently and activate different target genes[4]. 
The classical (canonical) NF-κB activation pathway is triggered by Th1 cytokines and is typified 
by the action of RelA(p65)–NF-κB1(p50) heterodimers, whilst the alternative (non-canonical) 
activation pathway signals through the adaptor protein NF-κB-inducing kinase (NIK). 
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Activation of this mechanism leads to nuclear translocation of transcriptionally active v-rel 
avian reticuloendotheliosis viral oncogene homolog B (RelB)–NF-κB2(p52) heterodimers. 
Signaling through either pathway can influence multiple different cellular functions and can 
exert effects that may appear contradictory. For example, both pro- and anti-apoptotic 
effects, as well as proliferation[5] and senescence[6] signals have been attributed to the 
classical activation pathway of NF-κB signaling. Because of the wide variation in outcomes 
following pathway activation, it is difficult to extrapolate the effects of NF-κB signaling from 
one context to another. Recent evidence has established that alternative activation pathway 
NF-κB signaling is important during the development of several gastrointestinal (GI) 
pathologies in mouse and man. This article seeks to review this evidence and to establish 
questions for future research. 
 
Literature search strategy  
A systematic search of the English language literature listed in the PubMed database up to 5th 
November 2015 was performed based on the following search terms: 
(NF-κB2 OR NFκB2 OR NF-kappaB2 OR NFkappaB2 OR NF-kB2 OR NFkB2 OR p52 OR p100 OR 
"alternative NF-κB" OR "alternative NFκB" OR "alternative NF-kappaB" OR "alternative 
NFkappaB" OR "alternative NF-kB" OR "alternative NFkB" OR "non-canonical" OR relB OR NIK 
OR IKKa OR MAP3K14 OR CHUCK) AND (stomach OR gastric OR intestine OR intestinal OR 
gastrointestinal OR colon OR colonic OR colorectal OR colitis OR Crohn's OR bowel OR 
oesophagus OR oesophageal OR esophagus OR esophageal OR Barrett's).  
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This search generated 316 results, of which 115 articles were retained following review of 
titles and abstracts. The full texts of these articles were acquired and used as the basis of this 
article; retrieved article reference lists were searched manually for other relevant literature. 
The scope of the article has been limited to the importance of the alternative NF-κB signaling 
pathway in the gastrointestinal tract, particularly during the development of cancers and pre-
malignant pathologies. Articles discussing the liver and pancreas only have not been included. 
 
The alternative NF-κB activation pathway 
The NF-κB/Rel family includes five members: RelA(p65), c-Rel, RelB, NF-κB1(p50/p105), and 
NF-κB2(p52/p100). Each possesses a structurally conserved 300 amino-acid sequence; the 
REL homology domain (RHD). In the unstimulated state, these proteins pool as homo- or 
heterodimers (of which there are at least 15 known combinations), predominantly within the 
cytoplasm[7]. Some of these dimers function exclusively in the classical NF-κB signaling 
pathway (figure 1a) and are beyond the scope of this article. Alternative NF-κB pathway 
activation leads to translocation of NF-κB2(p52)/RelB heterodimers into the nucleus, 
following which NF-κB2(p52) and RelB directly influence gene transcription. 
NF-κB mediated transcription is regulated by the inhibitors of NF-κB (IκB) (IκBα, IκBβ, IκBε, 
and Bcl-3) which are peptides that bind NF-κB protein dimers through residues containing 6 
to 7 ankyrin repeats. Interaction of IκB proteins with NF-κB protein dimers prevents the 
nuclear translocation of the NF-κB protein dimers. NF-κB2 is synthesized as a 100kDa protein, 
p100, which has a RHD within its N-terminus and a seven ankyrin repeat domain at its C-
terminus which confers intrinsic IκB activity (figure 1b) [8]. 
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Alternative pathway NF-κB activation is characterized by processing of p100 into p52, both of 
which dimerize with RelB (Figure 1b). p100 is processed by at least two kinases, NIK and IκB 
kinase α (IKKα). These kinases can be activated by ligand interaction with several cell-surface 
receptors, including CD40 ligand binding to CD40, B-cell activating factor (BAFF) binding to its 
receptors, Lymphotoxin β interacting with LTβR, lipopolysaccharide (LPS) binding to Toll-like 
receptor 4 (TLR4) and Receptor activator of nuclear factor kappa-B ligand (RANKL) binding to 
RANK[9]. The pathway can also be activated by oncogenic viruses including Epstein-Barr 
Virus[10].  
Upon ligand binding, tumour necrosis factor receptor-associated factors (TRAFs; such as 
TRAF2 and TRAF3) are recruited either directly or via other adaptor proteins to the 
intracellular domain of the activated receptor.  Unlike TRAF2 and TRAF5 that also regulate 
classical NF-κB signaling, TRAF3 only regulates the alternative NF-κB signaling pathway and 
directly binds to NIK, regulating NIK turnover[11]. NIK is continually degraded by the 
proteasome as a result of polyubiquitination by the cellular inhibitors of apoptosis (c-IAP 
1,2)/E2 ligase complex that is also recruited to TRAF3 (figure 1b).  As a result of TRAF3 complex 
recruitment to the activated receptor, TRAF3 is targeted for degradation by the proteasome 
which allows NIK to accumulate in the cytosol (figure 1c) [12]. Cytosol accumulated NIK 
becomes phosphorylated at threonine 559 by an incompletely described mechanism that may 
involve both autophosphorylation[13], and phosphorylation via zinc-finger-protein-91[14]. 
Subsequently, Thr559-phospho-NIK phosphorylates p100 at serine (Ser) residues 866 and 870 
acting as a docking molecule for recruitment of IKKα to p100. Recruitment of IKKα leads to 
phosphorylation of the N-terminus of NF-κB2(p100) at Ser 99, 108, 115 and 123 and at C-
terminal Ser 872. Beta-transducin repeat-containing protein (beta-TrCP), a component of the 
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SCF ubiquitin ligase complex is then recruited to phosphorylated NF-κB2(p100) leading to 
polyubiquitination of NF-κB2(p100) at lysine (Lys) 855 which targets NF-κB2 for partial 
proteasomal degradation, leading to generation of NF-κB2(p52)[15]. 
Activation of the alternative NF-κB signaling pathway is generally slower (~6-8 hours) than the 
classical activation pathway, leading to a delayed but sustained response which integrates 
with the acute-phase (~1.5 hours) response driven by classical NF-κB pathway activation[9, 
16]. Emerging evidence supports the concept that classical and alternative NF-κB activation 
pathways interact to induce coordinated and sustained immunological responses. Banoth and 
colleagues recently used systems level analysis to identify stimulus-specific crosstalk between 
the TLR4-activated canonical NF-κB activation pathway and LTβR-induced alternative NF-κB 
activation pathway signaling. They identified a positive-feedback loop that sustained the NF-
κB response. Using mouse embryonic fibroblasts, they demonstrated that the LTβR signal 
prolonged the TLR4-induced RelA response, by targeting newly-synthesized p100 for 
processing to p52, allowing formation of p65(RelA)-p52(NF-κB2) dimers. This led to increased 
expression of pro-inflammatory cytokines and chemokines[17]. Understanding the 
integration of different mechanisms of NF-κB activation is a key challenge for this field. 
 
Role of the alternative NF-κB activation pathway in gut development and repair 
Whilst expression of the classical NF-κB activation pathway components RelA and c-Rel can 
be found in many tissues and cell types, in health the expression of alternative pathway NF-
κB sub-units has more frequently been demonstrated in cells of the immune system. More 
recent data have however demonstrated constitutive expression of RelB within small 
intestinal Peyer’s patches[18] and of RelB and NF-κB2 (p100) in murine gastric epithelium[19]. 
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Animal models suggest that the alternative NF-κB activation pathway components NIK, NF-
κB2 and RelB are required for the normal development of small intestinal Peyer’s patches [20, 
21]. Peyer’s patches consist predominantly of immune cells which exist in close association 
with the specialized ‘dome’-like epithelium described as follicle-associated epithelium (FAE). 
The presence of RelB-expressing cells also appears essential for the differentiation of 
enterocytes into microfold cells (M-cells) which represent approximately 5% of epithelial cells 
within FAE. Functionally, M-cells are specialized to perform luminal antigen sampling and 
immune priming[22]. M-cells have been implicated in the initiation of granulomatous lesions 
in Crohn’s disease[23] and are thought to influence responses to gastrointestinal 
infections[24, 25], and colorectal carcinogenesis[26, 27]. Tahoun and colleagues found that 
stimulation of RelB-expressing FAE enterocytes with Salmonella enterica Typhimurium 
triggered autocrine activation by RANK ligand-RANK interaction induced the transcription 
factor Snail family zinc finger-2 (Slug) and resulted in transdifferentiation into M-cells[25]. The 
expression of glycoprotein-2 (GP2), a key receptor expressed on mature M-cells also appears 
to be dependent on the nuclear translocation of RelB[28].  
Whilst there is substantial evidence that RelB is involved in the development of Peyer’s 
patches and M-cells within FAE, the mechanisms involved remain unclear. Wang and 
colleagues demonstrated that Peyer’s patch development was dependent on stimulation of 
TNFR and LTβR[29], however the precise ligands for these receptors and the downstream 
effects of signaling via this pathway during the development of Peyer’s patches, have not yet 
been defined.  
There is also evidence that alternative pathway NF-κB signaling may influence gastric 
epithelial homeostasis. Mice lacking the COOH-terminal ankyrin repeat domain of p100 
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synthesize a truncated form of NF-κB2, which lacks the IκB activity of p100 but is able to 
dimerize with other NF-κB protein family members and can translocate to the nucleus to 
influence transcription. This models unimpeded alternative pathway NF-κB activation and 
leads to persistent translocation of NF-κB2-containing dimers to the nucleus. These animals 
exhibit massive gastric antral hyperplasia, have increased lymphocyte proliferation and die 
during early postnatal life due to complications arising from gastric outlet obstruction[30]. 
 
Alternative pathway NF-κB signaling in cancers of the gastrointestinal tract 
Inflammatory mediators influence many cellular functions that may promote development of 
a malignant phenotype[31]. Since NF-κB signaling regulates innate immune responses, 
influencing the expression of a set of target genes in epithelial and immune compartments 
including cytokines (e.g. TNF, interleukin (IL)-6 and IL-1β)[6, 32, 33], their receptors (TNF 
superfamily receptors) and other inflammatory mediators, including cell adhesion molecules 
such as vascular cell adhesion protein 1 (VCAM-1)[34, 35]  as well as genes involved in 
regulating the cell cycle such as cyclins and cyclin-dependent kinases[36-38] it is unsurprising 
that these processes also influence tumorigenesis. 
The majority of studies investigating NF-κB and cancers of the gastrointestinal tract have 
focused upon the classical activation pathway family members NF-κB1, RelA (p65) and c-Rel. 
However there is emerging evidence that alternative NF-κB activation pathway family 
members also play important roles during carcinogenesis throughout the GI tract. 
Esophageal cancer 
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Two histological subtypes of esophageal cancer exist, both of which develop on a background 
of chronic inflammation. Esophageal squamous carcinoma is associated with inflammation 
induced by extrinsic stimuli including cigarette smoking and alcohol consumption. Esophageal 
adenocarcinoma is also associated with these extrinsic risk factors, but is also associated with 
chronic gastroesophageal reflux, and occurs on a background of columnar metaplasia 
(Barrett’s esophagus). The epidemiology and pathophysiology of these conditions are distinct, 
with the incidence of both conditions increasing in western populations.  
In normal squamous esophageal tissue, the expression of NF-κB proteins is relatively low. 
However tissue samples from patients with esophageal squamous cell carcinoma showed 
increased expression of NF-κB1(p50/105), NF-κB2(p52/100) and RelA up to 18-fold[39]. In 
addition the anti-tumor activity of the hypo-methylating chemotherapeutic drug decitabine 
has been associated with increased expression of NF-κB2[40]. 
There are few data addressing the role of alternative pathway NF-κB signaling in gastro-
esophageal reflux disease, Barrett’s esophagus or esophageal adenocarcinoma in humans, 
however a recent study examined the role of reflux and smoking on the expression of  
alternative pathway NF-κB signaling components in the esophageal epithelium of mice. Using 
immunohistochemical techniques, it was demonstrated that the abundance of NIK was 
increased in the presence of either cigarette smoke alone or reflux alone[41]. One of the 
challenges of investigating the function of NF-κB pathways is the need to differentiate the 
abundance of proteins that signal within the pathway and their functional effects. These data 
provide inconclusive evidence that alternative pathway NF-κB signaling is involved in 
esophageal adenocarcinoma development, but support the need for further investigation of 
alternative pathway NF-κB signaling in this context. 
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Gastric Cancer 
The most important etiological factor during gastric carcinogenesis is infection with 
Helicobacter pylori[42-46]. H. pylori infection results in stereotypical pre-malignant gastric 
pathology progressing from atrophic gastritis through metaplasia into dysplasia and cancer. 
In humans this process develops over several decades; mouse infection with the closely 
related bacterium Helicobacter felis recapitulates this sequence of pathology over an 
accelerated timescale. We recently showed that, despite heavy colonization with H. felis, 
Nfkb2-/- mice developed minimal inflammatory cell infiltration, demonstrated a blunted 
cytokine response and did not develop the pre-malignant lesions associated with chronic H. 
felis infection[19] (Figure 2a-d).  
Other data have demonstrated in-vitro relevance for this pathway in response to H. pylori in 
both gastric epithelial and immune cell culture systems[19, 45, 46]. Hirata and colleagues 
showed that IKKα accumulates in AGS cells following H. pylori infection, but this did not lead 
to NF-κB2(p100) processing to NF-κB2(p52). The consequences of this are not clear, however 
it has been postulated that accumulation of cytosolic NF-κB2(p100) may inhibit nuclear NF-
κB2(p52) interaction with chromatin, leading to an altered transcriptional fingerprint[47]. 
Separately, H. pylori activation of NF-κB was shown to occur via a pathway requiring IKKα, 
IKKβ, and NIK in MKN45 and KATO III human gastric cancer cell lines. In this context, activation 
of NIK also required signaling via the adapter proteins TRAF2 and TRAF6[48]. Further evidence 
for the involvement of NIK was provided by Neumann and colleagues [41] who demonstrated 
that activation of NF-κB by H. pylori required the formation of a complex between p21-
activated kinase 1 (PAK1) and NIK[49].  
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In addition to the evidence that H. pylori can activate NF-κB via the alternative activation 
pathway in epithelial tissue, in-vitro processing of NF-κB2(p100) to NF-κB2(p52) has also been 
demonstrated in B lymphocytes in response to H. pylori infection[50]. This may have 
implications for the development of gastric MALT lymphomas. 
Further evidence that classical and alternative pathway NF-κB activation is relevant to 
Helicobacter induced pathology comes from the evidence that clarithromycin, one of the 
antibiotics used most frequently to eradicate H. pylori, modulates H. pylori-induced activation 
of NF-κB via both activation pathways in gastric cancer cells[51]. 
Colorectal cancer 
Sporadic colorectal cancers most commonly develop from adenomatous polyps[52]. These 
lesions develop as a consequence of the acquisition of stereotypical mutations over time. 
They occur in an otherwise non-inflamed colonic mucosa, but an inflammatory response to 
adenoma development is frequently identified. Despite this, few data regarding the 
importance of the alternative activation pathway of NF-κB signaling during sporadic colorectal 
carcinogenesis exist.  
Amongst the best characterized pathways involved in colorectal carcinogenesis is the WNT 
signaling pathway.  Activation of this pathway leads to stabilization of -catenin, which is 
observed in many colonic adenomas. There is increasing evidence for crosstalk between the 
NF-κB and WNT signaling pathways, with evidence that activation of NF-κB pathways may 
accelerate the loss of APC during colorectal adenoma development[53]. However there is 
little direct evidence to suggest that alternative pathway NF-κB signaling is involved. 
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There is circumstantial evidence that alternative pathway NF-κB signaling may exert an effect 
on sporadic colonic carcinogenesis. MicroRNA miR-518a-3p was observed to be down-
regulated in colon cancers in proportion to their size and TNM stage. This microRNA targets 
NIK for degradation, therefore its down-regulation leads to increased NIK abundance and 
subsequent activation of NIK dependent NF-κB pathways[54].  
In contrast to sporadic colon cancer, more has been published regarding the impact of 
alternative pathway NF-κB signaling during the development of colitis-associated colorectal 
cancer. Individuals with chronic inflammatory bowel disease (IBD), including Crohn’s disease 
and ulcerative colitis, have an increased risk of colorectal cancer[55]. In these patients, 
colorectal tumors develop on the background of an inflamed colonic mucosa, and rather than 
developing as discrete polyps, usually arise within fields of flat dysplastic mucosa[52]. 
The most established murine model of colitis-associated cancer uses a single dose of the DNA-
damaging agent azoxymethane (AOM) followed by several doses of dextran sulfate sodium 
(DSS) to induce chronic colitis (AOM/DSS)[56]. We have reported that Nfkb2-/- mice are 
resistant to AOM/DSS-induced colitis-associated adenoma development[57]. Transgenic mice 
developed fewer dysplastic colonic lesions, were less susceptible to DSS-induced colitis 
(Figure 2i-p), and had a more robust apoptotic response following DNA damage compared to 
wild-type controls. 
In contrast to Nfkb2-/- mice, Nlrp12-/- mice exhibited increased susceptibility to AOM/DSS 
induced colitis-associated colorectal cancer; polyps isolated from these mice had increased 
activation of the alternative NF-κB activation pathway. Nlrp12-/- primary dendritic cells 
showed elevated NIK expression, p100 processing to p52 and reduced abundance of TRAF3. 
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This provides evidence for NLRP12 acting as a checkpoint on signaling via the alternative NF-
κB activation pathway during inflammation and tumorigenesis[58].  
 
Alternative pathway NF-κB signaling in conditions of the GI tract that predispose to cancer 
Gastrointestinal tract infections 
Chronic bacterial and helminth infections are established risk factors for the development of 
malignancy. The best-characterized organism is H. pylori, which plays a major role in gastric 
carcinogenesis as discussed above. Several lines of evidence have identified that alternative 
pathway NF-κB signaling is important in the host response to gastrointestinal pathogens. 
Infection with the foodborne pathogen Salmonella Typhimurium has been shown to promote 
the differentiation of M-cells in the small intestine through induction of RANK, and its ligand 
RANKL, leading to increased differentiation of M-cells and increased uptake of the pathogen. 
In addition to the evidence described above that S. Typhimurium may induce M-cell 
transdifferentiation via an alternative activation NF-κB pathway dependent mechanism  
Tahoun and colleagues[25] have also demonstrated that translocation of S. Typhimurium was 
significantly reduced in the presence of the NF-κB inhibitor SN50, suggesting that NF-κB 
signaling plays a role in enhancing S. Typhimurium translocation across the epithelium. Whilst 
this organism is not directly associated with gastrointestinal carcinogenesis, these 
mechanisms offer a paradigm by which other carcinogenic organisms may influence epithelial 
events via NF-κB signaling.  
Banoth and colleagues demonstrated that C57BL/6 mice infected with Citrobacter rodentium 
developed colitis with epithelial accumulation of p100. Nfkb2-/- mice infected with C. 
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rodentium were more susceptible to developing colitis than wild-type mice. Using reciprocal 
bone marrow transfer experiments, Nfkb2-/- mice given wild-type mouse bone marrow lost 
weight and had 100% mortality before day 10, whereas wild-type mice given either wild-type 
or Nfkb2-/- bone marrow did not lose weight or show increased mortality. These findings 
indicate that NF-κB2 expression within the non-myeloid compartment is involved in limiting 
the severity of C. rodentium associated colitis[17].  
Alternative pathway NF-κB signaling is also implicated in the orchestration of immune 
responses to gastrointestinal helminth infestation. C57BL/6 mice generate a marked Th2 
immune response following colonization with the whipworm Trichuris muris. This induces 
rapid expulsion of the helminth and clearance of infestation within 35 days of colonization. In 
contrast, Nfkb2-/- mice develop a chronic, persistent infestation with an impaired Th2 cytokine 
response[59]. More recently, an immunosuppressed man with histoplasmosis and extra-
intestinal Hymenolepis nana infection was found to possess abnormal proliferative cells which 
displayed malignant characteristics. Upon investigation, the cells were found to be consistent 
with tapeworm stem cells; this was the first report of parasite-derived cancer cells in a human, 
further demonstrating the link between infection and cancer, and highlighting its relevance 
when considering GI exposure to helminths[60]. 
Inflammatory bowel disease  
Chronic idiopathic inflammatory bowel diseases that affect the colon increase an individual’s 
risk of developing colorectal cancer in proportion to the duration of disease and the extent of 
inflammation[61-64], and evidence suggests that treatments that decrease an individual’s 
inflammatory burden, including azathioprine[65] and 5-amino salicylic acid preparations [66] 
may decrease the risk of developing colitis-associated colon cancer.  
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The alternative NF-κB activation pathway has not to date been targeted specifically for the 
development of novel therapeutics for IBD. This is likely due to the fact that most studies in 
IBD have found activation of the classical activation pathway, but not the alternative 
pathway[67-69]. For example, Ardite and colleagues used electromobility shift assays to 
detect NF-κB components in colonic biopsy samples from patients with active IBD who had 
been treated with steroids. The classical NF-κB activation pathway subunit p50 was found in 
inflamed tissue from IBD patients but p65, p52, c-Rel and RelB were not detected[67].  
In contrast to the findings in humans, mouse models of colitis induced by carrageenan and 
DSS have demonstrated that classical and alternative NF-κB signaling pathways are 
activated[70-73] during colonic inflammation. One of the earliest events in IBD is thought to 
be impairment of enteric mucosal barrier function. We have modeled this by administration 
of LPS from Escherichia coli to C57BL/6 mice and mice lacking NF-κB2. We demonstrated that 
Nfkb2-/- mice were more resistant to LPS-induced small intestinal epithelial cell shedding 
compared to wild-type mice[71] (Figure 2e-h). Separately and as described above, we 
demonstrated that the severity of DSS-induced acute colitis was reduced in Nfkb2-/- mice 
relative to wild-type mice[57](figure 2i-p). 
Our studies, and those of Banoth suggest that there may be a function for these pathways in 
the regulation of enteral inflammation, suggesting that targeting alternative pathway NF-κB 
signaling in IBD may be a fruitful avenue for further research. 
One element of IBD therapy in which tangential evidence for alternative pathway NF-κB 
signaling has been accrued is the role of functional foods. This is of particular interest in the 
context of Crohn’s disease, where dietary modification with liquid feeding has been shown to 
offer therapeutic benefits, particularly in pediatric patients. 
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A study examining the role of parenteral nutrition in IBD demonstrated that a lack of enteral 
stimulation in mice led to globally reduced expression of NF-κB proteins in Peyer’s 
patches[74]. Given the data that implicate RelB in Peyer’s patch development, and the role 
that Peyer’s patches play in immune priming these findings suggest that diet induced NF-κB 
signaling may influence GI immune tolerance.  
In contrast the use of dietary flaxseed to attempt to ameliorate experimental colitis was found 
to exacerbate DSS-induced colitis in mice, which was associated with an increase in expression 
of RelB in colonic tissue[72]. Together these studies highlight the functional effect that foods 
may have on NF-κB alternative pathway signaling in the gastrointestinal tract.  
Celiac Disease 
Gluten sensitive enteropathy, or celiac disease, confers an increased risk of small bowel 
adenocarcinoma and small bowel lymphoma, however due to the rarity of these cases it is 
difficult to accurately quantify the degree of increased risk[75]. Recent data have identified 
that increased expression of NFKB2 in patients with celiac disease, irrespective of their 
adherence to a gluten free diet[76]. Currently it is not clear whether this association has any 
impact on the prevalence or biology of small bowel malignancies. 
Discussion  
Several recent studies have highlighted the importance of alternative pathway NF-κB 
signaling in addition to the more widely studied classical NF-κB signaling pathway during the 
development and progression of both inflammation-associated cancers of the GI tract and 
sporadic cancers which have an inflammatory element. Some elements of NF-κB signaling 
pathways and their implications for disease have been well characterized, but investigation 
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in other areas is lacking. In particular, gaps exist in our understanding of these pathways in 
the formation of esophageal cancers and the role, if any, played by the gastrointestinal 
microbiome in regulating them. 
Most of the studies reported to date have relied on relatively imprecise tools to characterize 
the function of NF-κB signaling pathways, for instance the observation that NF-κB activation 
events may be localized to specific anatomical structures within in the GI tract (e.g. Peyer’s 
patches) suggests that previous studies which have assessed NF-κB activation events in whole 
tissue preparations should be interpreted with caution. Many investigations have also relied 
on either transgenic mice in which the stoichiometry of different pathway members is 
fundamentally altered, or have used semi-quantitative analyses of protein abundance to try 
to explain the complexities of these pathways. 
Banoth and colleagues have demonstrated a different approach to research in this field by 
employing systems medicine techniques to characterize interactions between multiple 
components of this complex transcriptional regulating machinery. In the future, increasingly 
complex mathematical modeling will be required to better understand how inflammation is 
regulated by NF-κB signaling in real-time, and to apply these models to complex systems, 
including the pathogenesis of cancer. To achieve this, close collaboration between 
researchers with diverse backgrounds including clinician scientists, molecular biologists and 
systems biologists will be necessary. 
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